Table 1.

Clinical features, biochemical results, radiological findings and management of patients within the study cohort

Cancer disease groupICICyclePresenting complaintBlood pressure (mmHg)Random blood glucose (mmol/L)Sodium (mmol/L) (133–146)Cortisol (nmol/L)ACTH (ng/L) (5–46)TSH (mU/L) (0.4–5.0)Free T4 (pmol/L) (10–22)MRI scan of the pituitaryTime to OPD endo review (days)
Combination ICI therapy
MelanomaIpi/Nivo1Headache150/807.9138<50<50.139.0NAD6
Headache/fatigue/postural dizziness110/706.9132<50<50.0510.8Patient did not tolerate MRI8
Headache/fatigue110/703.7131<50<59.0114.1NAD8
Fatigue/nausea/headache110/703.7131<50<50.0315.9Pituitary inflamed8
RenalIpi/Nivo4Headache/fatigue120/706.8134<50<5<0.0214.4NAD7
3Headache/fatigue/blurred vision140/705.3130<50<5<0.0219.8
Contra-indicated4Nivo; previously Ipi/Nivo8Fatigue/nausea/postural dizziness110/705.5136<50107.1712.3NAD13
Single-agent PD-1 therapy
ColorectalNivo6Headache/fatigue140/705.8125<50<55.6118.1NAD7
Pem6Fatigue110/704.7139<50<51.5315.4Not done7
GastricNivo4Fatigue140/754.7133<50<535.795.5NAD9
MelanomaPem2Headache/fatigue110/706139<50<52.7610.7NAD8
Nivo4Headache/ fatigue/postural dizziness140/707.0141<50<50.2716.4Not tolerated7
NSCLCPem2Headache/fatigue100/604.9129<50<57.7215.3NAD13
13Fatigue/postural dizziness90/502.9135<5060.2519.5NAD8
  • ACTH = adrenocorticotrophic hormone; BP = blood pressure; Endo = endocrinology; ICI = immune checkpoint inhibitor; Ipi = ipilimumab; MRI = magnetic resonance imaging; Nivo = nivolumab; NSCLC = non-small cell lung cancer; OPD = outpatient department; TSH = thyroid-stimulating hormone.